Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
VIVUS (VVUS) Lower; Data Shows Unexpected Drop in Qsymia Prescriptions for Week 6 - BI
November 5, 2012 10:16 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is lower on the session following new prescription data for Qsymia in its sixth week.
Bloomberg Industries noted that prescriptions showed an "unexpected decline" for the week, falling 46 percent over the prior week. BI thinks this... More
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
October 26, 2012 11:58 AM EDTVIVUS (Nasdaq: VVUS) Qsymia is gaining more and more traction, according to the latest data from Bloomberg Industries and Healthcare Analytics.
According to the data, Qsymia prescriptions were up 30 percent from the prior week, with over 700 physicians prescribing the obesity pill. Of the... More
VIVUS (VVUS) Qsymia Prescriptions Keep Chugging, Gain 27%+ Last Week
October 22, 2012 10:08 AM EDTVIVUS (Nasdaq: VVUS) is lower Monday amid new data for the fourth-week of its Qsymia roll out showing continued market penetration.
According to data compiled by Cowen & Company, Qsymia had 1,626 new prescriptions for the week ended October 12th, a 27 percent jump from 1,278... More
